The filing is a routine advance notice of a small sale by a former director. Monitor whether the sale actually executes, but no material read-through for MRNA stock. The insider's status as a former director reduces signaling significance.
MRNA drugs
MRNA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 18 $63.96entry
- T+1 · 5mo ago −7.22%α −6.90% · $59.35
- T+5 · 5mo ago −6.58%α −4.92% · $59.75
- T+20 · 4mo ago −1.27%α −1.80% · $63.15
- T+60 · 2mo ago +129.35%α +127.45% · $146.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Former director Paul Sagan filed a Form 144 notice of intent to sell 25,770 shares of Moderna common stock, valued at approximately $1.66 million, acquired via stock option exercise. The proposed sale is small relative to Moderna's $24.5B market cap and represents a routine insider transaction with limited signaling value.
Key Facts
- Former director Paul Sagan filed Form 144 to sell 25,770 shares of MRNA common stock.
- Estimated market value of proposed sale: $1,663,874.56.
- Shares were acquired through a stock option exercise on the same date (06/18/2026).
- Sale represents ~0.007% of Moderna's $24.5B market cap.
- Only one other insider sale ($2.7M) was reported in the prior 30 days.
Financial Impact
Proposed sale of ~$1.66M, negligible relative to $24.5B market cap.
Risk Factors
- No material risks identified from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-004772 |
| Document: 0001959173-26-004772-index.html | 0001959173-26-004772 |
| Document: 0001959173-26-004772.txt | 0001959173-26-004772 |
Track record
26 reports on MRNA
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers